focus -WSS

focus

author：comprehensive 2025-09-29 20:50:44 - browse：7492

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： As obesity drug market grows, telehealth companies court payers

focus

WSS

EQRx, failed developer of low

EQRx, failed developer of low

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

People can get long Covid without testing positive for virus: Study

Lawsuit alleges UnitedHealth Group unit illegally denied claims

FDA advisory panel to debate high blood pressure devices

hotspot

focus

entertainment

Novavax promises a turnaround & Lilly roils the obesity market

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Drug repurposing or repositioning? The language matters

Micronoma's microbiome cancer diagnostic approach under fire

Heart attack and stroke risk calculators need revising

Amazon expands telehealth clinic nationwide

Tori Bowie and the unacceptable rates of Black maternal death

Health officials lay out plans to cope with respiratory virus season

Walensky prepares to leave CDC — and Congress — behind

New safety details link Apellis eye drug to rare cases of blindness

explore

Mitch McConnell episode has important public health takeaway

5 important ways Henrietta Lacks changed medical science

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

What the airline industry can learn from medicine

Trans patients at the end of life deserve respect and dignity

The high personal cost of affirmative action for Black doctors

focus

hotspot

Wikipedia

Wikipedia